118 related articles for article (PubMed ID: 28141936)
21. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
22. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.
Cogle CR; Iannacone MR; Yu D; Cole AL; Imanirad I; Yan L; Mackinnon JA; List AF; Rollison DE
Leuk Res; 2014 Jan; 38(1):71-5. PubMed ID: 24280283
[TBL] [Abstract][Full Text] [Related]
23. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
24. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
25. Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study.
Lesegretain A; Brunner A; King AJ; Laadem A; Fell G; Fathi AT
Leuk Res; 2023 Feb; 125():107006. PubMed ID: 36580877
[TBL] [Abstract][Full Text] [Related]
26. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
Hui CH; Horvath N; Lewis I; To LB; Szabo F
Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
[TBL] [Abstract][Full Text] [Related]
27. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
28. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
29. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
30. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
31. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
[TBL] [Abstract][Full Text] [Related]
32. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
[TBL] [Abstract][Full Text] [Related]
33. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.
Johnson RC; Kurzer JH; Greenberg PL; Gratzinger D
Am J Clin Pathol; 2014 Dec; 142(6):795-802. PubMed ID: 25389333
[TBL] [Abstract][Full Text] [Related]
35. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
Cogle CR; Craig BM; Rollison DE; List AF
Blood; 2011 Jun; 117(26):7121-5. PubMed ID: 21531980
[TBL] [Abstract][Full Text] [Related]
36. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Ferrero D; Crisà E; Marmont F; Audisio E; Frairia C; Giai V; Gatti T; Festuccia M; Bruno B; Riera L; Passera R; Boccadoro M
Ann Hematol; 2014 Aug; 93(8):1391-400. PubMed ID: 24705888
[TBL] [Abstract][Full Text] [Related]
37. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
38. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
[TBL] [Abstract][Full Text] [Related]
39. Patterns of blood product use among patients with myelodysplastic syndrome.
Ramsey SD; McCune JS; Blough DK; McDermott CL; Beck SJ; López JA; Deeg HJ
Vox Sang; 2012 May; 102(4):331-7. PubMed ID: 22115321
[TBL] [Abstract][Full Text] [Related]
40. Effect of initial body mass index on survival outcome of patients with myelodysplastic syndrome: a single-center retrospective study.
Xu X; Zhang Q; Hu G; Zhuang Q; Xing C; Shi Y; Liang B; Shen Z; Jiang S; Yu K; Feng J
Leuk Lymphoma; 2018 Jan; 59(1):129-137. PubMed ID: 28573898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]